Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized crossover and open-label trial of dasiglucagon in children with congenital hyperinsulinism
2017-004545-24Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dasiglucagon in congenital hyperinsulinism (HI) and hyperinsulinism (HI) (2 arms), sponsored by Zealand Pharma. Primary endpoints: Efficacy: reduction in glucose requirements (Part 1) and Safety and tolerability of dasiglucagon (Part 1 and Part 2). Started Sep 2018; status: completed.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)hyperinsulinism (HI)
Beyond the preview
Go deeper on 2017-004545-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004545-24.